Skip to Main Content

Cytokinetics and Amgen said Thursday that an experimental heart drug reduced the risk of hospitalizations and other treatments for patients with chronic heart failure in a large cardiovascular outcomes clinical trial.

But while the study achieved its main goal, the treatment effect was marginal and the drug, called omecamtiv mecarbil, did not help heart failure patients live longer, the companies said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!